These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31626872)

  • 1. Impaired chloride homeostasis in epilepsy: Molecular basis, impact on treatment, and current treatment approaches.
    Auer T; Schreppel P; Erker T; Schwarzer C
    Pharmacol Ther; 2020 Jan; 205():107422. PubMed ID: 31626872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of novel bumetanide derivatives for epilepsy treatment.
    Auer T; Schreppel P; Erker T; Schwarzer C
    Neuropharmacology; 2020 Jan; 162():107754. PubMed ID: 31476353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide.
    Töllner K; Brandt C; Römermann K; Löscher W
    Eur J Pharmacol; 2015 Jan; 746():167-73. PubMed ID: 25449033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
    Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
    Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments.
    Löscher W; Puskarjov M; Kaila K
    Neuropharmacology; 2013 Jun; 69():62-74. PubMed ID: 22705273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
    Dzhala VI; Brumback AC; Staley KJ
    Ann Neurol; 2008 Feb; 63(2):222-35. PubMed ID: 17918265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy.
    Töpfer M; Töllner K; Brandt C; Twele F; Bröer S; Löscher W
    Eur J Neurosci; 2014 Feb; 39(4):673-87. PubMed ID: 24251546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.
    Töllner K; Brandt C; Töpfer M; Brunhofer G; Erker T; Gabriel M; Feit PW; Lindfors J; Kaila K; Löscher W
    Ann Neurol; 2014 Apr; 75(4):550-62. PubMed ID: 24615913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis.
    Dzhala V; Staley KJ
    CNS Neurosci Ther; 2015 Feb; 21(2):173-80. PubMed ID: 25495911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
    Lykke K; Töllner K; Feit PW; Erker T; MacAulay N; Löscher W
    Epilepsy Behav; 2016 Jun; 59():42-9. PubMed ID: 27088517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
    Kahle KT; Staley KJ
    Neurosurg Focus; 2008 Sep; 25(3):E22. PubMed ID: 18759624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS pharmacology of NKCC1 inhibitors.
    Löscher W; Kaila K
    Neuropharmacology; 2022 Mar; 205():108910. PubMed ID: 34883135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
    Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
    Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
    Hampel P; Römermann K; MacAulay N; Löscher W
    Sci Rep; 2018 Jun; 8(1):9877. PubMed ID: 29959396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
    Gharaylou Z; Tafakhori A; Agah E; Aghamollaii V; Kebriaeezadeh A; Hadjighassem M
    CNS Drugs; 2019 Mar; 33(3):283-291. PubMed ID: 30784026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders.
    Ben-Ari Y
    Trends Neurosci; 2017 Sep; 40(9):536-554. PubMed ID: 28818303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.
    Sivakumaran S; Maguire J
    Epilepsia; 2016 Feb; 57(2):222-32. PubMed ID: 26659482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological tools to target NKCC1 in brain disorders.
    Savardi A; Borgogno M; De Vivo M; Cancedda L
    Trends Pharmacol Sci; 2021 Dec; 42(12):1009-1034. PubMed ID: 34620512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy.
    Margineanu DG; Klitgaard H
    Epilepsy Res; 2006 May; 69(2):93-9. PubMed ID: 16495037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKCC1 transporter facilitates seizures in the developing brain.
    Dzhala VI; Talos DM; Sdrulla DA; Brumback AC; Mathews GC; Benke TA; Delpire E; Jensen FE; Staley KJ
    Nat Med; 2005 Nov; 11(11):1205-13. PubMed ID: 16227993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.